SEARCH

SEARCH BY CITATION

References

  • Allgayer H, Ahnfelt NO, Kruis W, Klotz U, Frank-Holmberg K, Soderberg HN et al. (1989). Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 97: 3841.
  • Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P et al. (2008). Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 28: 734741.
  • van Bodegraven AA, Mulder CJ (2006). Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J Gastroenterol 12: 61156123.
  • de Boer NK, van Bodegraven AA, Jharap B, De Graaf P, Mulder CJ (2007a). Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 4: 686694.
  • de Boer NK, Wong DR, Jharap B, De Graaf P, Hooymans PM, Mulder CJ et al. (2007b). Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 102: 27472753.
    Direct Link:
  • Bokemeyer B, Teml A, Roggel C, Hartmann P, Fischer C, Schaeffeler E et al. (2007). Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 26: 217225.
  • Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B et al. (2000). F. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 6: 10251030.
  • Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ et al. (2004). Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 26: 311318.
  • Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y (2002). Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 16: 7985.
  • Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Muller R et al. (2007). Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Ther Drug Monit 29: 15.
  • Dubinsky, M. C., Yang, H., Hassard, P. V., Seidman, E. G., Kam, L. Y., Abreu, M. T. et al. (2002). 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122: 904915.
  • Gisbert JP, Gomollón F. (2008). Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 7: 17831800.
    Direct Link:
  • Gilissen LP, Bierau J, Derijks LJ, Bos LP, Hooymans PM, van Gennip A et al. (2005). The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 22: 605611.
  • de Graaf P, De Boer NK, Jharap B, Mulder CJ, van Bodegraven AA, Veldkamp AI (2008). Stability of thiopurine metabolites: a potential analytical bias. Clin Chem 54: 216218.
  • Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P et al. (2006). 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 12: 251257.
  • Hussain FN, Ajjan RA, Moustafa M, Anderson JC, Riley SA (1998). Simple method for the determination of 5-aminosalicylic and N-acetyl-5-aminosalicylic acid in rectal tissue biopsies. J Chromatogr B Biomed Sci Appl 716: 257266.
  • Karner S, Shi S, Fischer C, Schaeffeler E, Neurath MF, Herrlinger KR et al. (2010) Determination of 6-thioguanosine diphosphate and triphosphate and nucleoside diphosphate kinase activity in erythrocytes: novel targets for thiopurine therapy? Ther Drug Monit [Epub ahead of print].
  • Klotz U (1985). Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 10: 285302.
  • Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM et al. (1997). Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 62: 464475.
  • Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV et al. (2001) Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 49: 656664.
  • Neurath MF, Kiesslich R, Teichgraber U, Fischer C, Hofmann U, Eichelbaum M et al. (2005). 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenterol Hepatol 3: 10071014.
  • Nygaard U, Toft N, Schmiegelow K (2004). Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 75: 274281.
  • Osterman MT, Kundu R, Lichtenstein GR, Lewis JD (2006). Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130: 10471053.
  • Poppe D, Tiede I, Fritz G, Becker C, Bartsch B, Wirtz S, et al. (2006). Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 176: 640651.
  • Sandborn WJ, Hanauer SB (2003). Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 17: 2942.
  • Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M Et al. (2004). Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 7: 407417.
  • Schwab M, Schäffeler E, Marx C, Fischer C, Lang T, Behrens C et al. (2002). Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 6: 429436.
  • Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB (2007). Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 5: 209214.
  • Szumlanski CL, Weinshilboum RM (1995). Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 39: 456459.
  • Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M (2007). Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 46: 187208.
  • Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. (2003). CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111: 11331145.
  • Vikingsson S, Carlsson B, Almer SH, Peterson C (2009). Monitoring of thiopurine metabolites in patients with inflammatory bowel disease-what is actually measured? Ther Drug Monit 31: 345350.
  • Xin H, Fischer C, Schwab M, Klotz U (2005). Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Aliment Pharmacol Ther 21: 11051109.